December 16 2024- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer.

Former CEO and founder Sander van Deventer, will become President of R&D, and will continue to drive the development of VectorY’s pipeline including its lead program, VTx-002, a novel vectorized antibody targeting TDP-43 for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is currently in IND-enabling studies.

Concurrent with these activities, the Company has expanded its US presence by opening an office in Boston.

Also Read : Adagio Medical selects Todd Usen as new CEO and Director

“On behalf of the Board, I’m delighted to welcome Jim as our new CEO. He brings a significant degree of experience, vision and leadership which will play a critical role at this juncture of VectorY’s development as we advance our lead program. Jim’s experience complements and will build on the great progress that Sander and the VectorY team have achieved over the past four years.” said Adam Rosenberg, Chairman of VectorY Therapeutics said

“I am excited about Jim joining the company as CEO. His experience of taking an innovative drug development pipeline and driving it forward is immensely valuable to VectorY as we approach the clinic,” added Sander van Deventer.

“I am delighted to join VectorY at such a pivotal time,” said Jim Scibetta. “VectorY has impressive early data behind its technology and preclinical programs, and the Company is supported by a leading investor syndicate. There is a clear path to achieving clinical data for its lead asset, VTx-002, with considerable future potential from the pipeline emanating from the novel VectorY platform.”